Procyon Advisors, LLC Vertex Pharmaceuticals Inc Transaction History

Procyon Advisors, LLC

$1.44 Billion
Q3 2024

A detailed history of Procyon Advisors, LLC transactions in Vertex Pharmaceuticals Inc stock. As of the latest transaction made, Procyon Advisors, LLC holds 15,010 shares of VRTX stock, worth $6.16 Million. This represents 0.49% of its overall portfolio holdings.

Number of Shares

15,010

Previous 14,853 1.06%

Holding current value

$6.16 Million

Previous $6.96 Million 0.27%

% of portfolio

0.49%

Previous 0.52%

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Oct 11, 2024	BUY	$460.0 - $505.78 $72,220 - $79,407	157 Added 1.06%	15,010 $6.98 Million
Q2 2024 Aug 02, 2024	BUY	$392.81 - $485.53 $208,189 - $257,330	530 Added 3.7%	14,853 $6.96 Million
Q1 2024 Apr 15, 2024	BUY	$407.69 - $446.08 $259,290 - $283,706	636 Added 4.65%	14,323 $5.99 Million
Q4 2023 Jan 18, 2024	BUY	$343.0 - $410.68 $322,077 - $385,628	939 Added 7.37%	13,687 $5.57 Million
Q3 2023 Oct 10, 2023	BUY	$338.18 - $362.46 $1.82 Million - $1.95 Million	5,375 Added 72.9%	12,748 $4.43 Million
Q2 2023 Jul 17, 2023	BUY	$314.42 - $351.91 $1.27 Million - $1.42 Million	4,028 Added 120.42%	7,373 $2.59 Million
Q1 2023 Apr 10, 2023	BUY	$283.23 - $323.1 $182,116 - $207,753	643 Added 23.8%	3,345 $1.05 Million
Q4 2022 Jan 19, 2023	BUY	$285.76 - $321.48 $406,922 - $457,787	1,424 Added 111.42%	2,702 $0
Q3 2022 Oct 17, 2022	SELL	$273.83 - $305.53 $24,097 - $26,886	-88 Reduced 6.44%	1,278 $370,000
Q2 2022 Jul 11, 2022	BUY	$234.96 - $292.55 $8,693 - $10,824	37 Added 2.78%	1,366 $385,000
Q1 2022 Apr 18, 2022	BUY	$221.42 - $260.97 $294,267 - $346,829	1,329 New	1,329 $347,000
Q3 2020 Oct 22, 2020	SELL	$255.65 - $303.1 $69,536 - $82,443	-272 Closed	0 $0
Q4 2019 Feb 21, 2020	BUY	$166.71 - $223.91 $45,345 - $60,903	272 New	272 $60,000

Others Institutions Holding VRTX

# of Institutions

1,724

Shares Held

221M

Call Options Held

1.58M

Put Options Held

1.36M

View Full List

About VERTEX PHARMACEUTICALS INC

Ticker VRTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 256,691,008
Market Cap $105B
Description
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...

More about VRTX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Procyon Advisors, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Procyon Advisors, LLC with notifications on news.

Account

Procyon Advisors, LLC Vertex Pharmaceuticals Inc Transaction History